您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策
您当前的位置:首页>>研究报告>>药物综合

2016-2026年风湿性关节炎药物市场
Rheumatoid Arthritis (RA) Drugs Market 2016-2026

2016-2026年风湿性关节炎药物市场
【报告编号】:No.25980
【发布时间】:2016-07
【关 键 字】:Rheumatoid Arthritis Drugs   风湿性关节炎药物   
【报告页数】:162页
【报告价格】:电子版:2639美元
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 药物综合行业的相关报告
DESCRIPTION
 
Rheumatoid Arthritis - New Study Showing You Those Drugs' Commercial Potentials
 
Where is the arthritic treatments market heading? Visiongain's updated report gives you forecasted revenues to 2026 for drugs treating rheumatoid arthritis (RA). There you find R&D trends, sales forecasting and commercial opportunities.
 
Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.
 
Read on to scan features of that industry, find what drives it, and see what its future market could be worth.
 
Forecasts and other analyses to help you assess the RA drugs market
 
Our report shows you revenue forecasts to 2026, sales results, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and R&D. Our 161 page report gives 67 tables and 65 charts to help your work.
 
With our study you can stay ahead in knowledge, benefiting your research, analyses, plans and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis.
 
There is rising need worldwide for drugs treating arthritis. Our work helps you find markets, products and developments with most commercial promise.
 
The following sections show how you benefit from our new study.
 
Discover sales predictions for that overall world market and submarkets
 
Along with revenue prediction for the overall world market for treating RA, our work shows you forecasts to 2026 for two main submarkets:
Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
Non-biologics (other therapeutic molecules).
 
For the non-biologics submarket, you get three further revenue breakdowns to 2026:
NSAIDs
sDMARDs
Others agents (grouped).
From 2016, how will the RA drugs market expand? Which parts will most prosper? For anti-rheumatic medicines, our report helps you identify sales potentials and find opportunities.
 
Our investigation also discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.
 
 
See revenue forecasts for 11 leading drugs
 
Our study forecasts revenues of 11 leading products for rheumatoid arthritis, including the following drugs:
Humira (adalimumab)
Enbrel (etanercept)
Remicade (infliximab)
Rituxan (rituximab)
Actemra (tocilizumab)
Orencia (abatacept).
With our analysis you discover how high sales can go, to 2026, finding drugs and years with highest predicted revenues and growth. You also assess competition, exploring trends, challenges and opportunities.
 
Our analysis also divides its overall world RA revenue forecast into geographical segments.
 
What sales and growth potentials for leading countries?
 
In developed and developing countries - especially India and China - there remain many opportunities for expanded selling of drugs to treat rheumatoid arthritis. Our study shows you individual revenue forecasts to 2026 for eleven national markets:
US
Japan
Germany, France, UK, Italy and Spain (EU5)
Brazil, Russia, India and China (BRIC).
That way you discover progress and outlooks. You assess the industry's future - hear about developments and find what they mean.
 
Our analysis shows revenue growth will occur in established pharma markets and in emerging countries. In particular, product launches from 2016 to 2026 will change anti-rheumatic drug prescribing and the commercial landscape. See what is possible.
 
Research and development - assess innovation, trends and possibilities
 
What about R&D - the pipeline for new RA drugs? Our study shows you developmental trends for these agents and others:
IL-6 inhibitors
JAK inhibitors
BTK inhibitors.
In our work you assess innovations, hearing about developments and finding their meaning. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Assess those firms' prospects.
 
Our study explains, also discussing forces affecting those companies and their market.
 
What affects the anti-arthritic drugs industry and market?
 
Our report discusses issues and events affecting that industry and market from 2016, including these developments:
Biologics, including biosimilars
Corticosteroids and other agents (e.g. JAK inhibitors)
Demand for more-efficacious and better-tolerated drugs
Need for less invasive routes of administration - drug delivery
Biosimilars and generics as challengers to original-branded medicines
Adalimumab, etanercept, infliximab and rituximab biosimilars
Regional variability in biosimilar approval.
That way you explore technological, economic, social and political questions, assessing outlooks for that business.
 
Our investigation also lets you analyse the RA treatment industry's strengths, weaknesses, opportunities and threats. Discover what the future holds.
 
Leading companies and 2020 market value
 
What happens next? Our study predicts the overall world market for those anti-arthritic drugs will reach $34.6bn in 2020. From 2016 sales will rise.
 
Our analyses show you what products and organisations hold greatest potential, including these leading companies:
AbbVie
Roche
J&J
Amgen
Pfizer
Merck & Co.
Prospects for arthritic R&D are encouraging, and from 2016 there will arise opportunities, including product launches. Our work shows you technological, clinical and commercial possibilities, helping you stay ahead in knowledge.
 
6 main ways Rheumatoid Arthritis (RA) Drugs Market 2016-2026 helps your work
 
In particular our investigation gives you the following knowledge to help your research, plans, decisions and presentations:
Revenues to 2026 for the overall rheumatoid arthritis drugs market and for 5 world-level submarkets - discover sales and growth potentials
Revenues to 2026 for 11 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
Forecasts to 2026 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see national sales potentials, finding the best regions for revenues and sales growth
R&D for treating rheumatoid arthritis - investigate technologies and progress, assessing medical and commercial possibilities
Discussions of leading companies, including profiles of 8 leading players - hear about strategies, capabilities, results and outlooks
Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.
That investigation, by our in-house analysts in the UK, gives knowledge to benefit your work. Our study shows information you find nowhere else, helping you succeed.
 
Independent data to benefit your authority on treating rheumatoid arthritis
 
Our report gives you independent analysis. It shows competitive intelligence found only in our study, helping you assess technological and commercial potentials.
 
With that report you are less likely to fall behind in information or miss opportunity. Discover how you could benefit your analyses, plans and decisions, also saving time and helping your influence.
 
So explore the future of drugs treating rheumatoid arthritis. In our study you find data, trends, opportunities and sales predictions. Stay ahead by getting our new report here now.
 
visiongain is a trading partner with the US Federal Government.
 
Table of Contents
 
1. Report Overview
1.1. Rheumatoid Arthritis Overview
1.2. Rheumatoid Arthritis Market Segmentation
1.3. Why You Should Read this Report
1.4. How this Report Delivers
1.5. Main Questions Answered by this Report
1.6. Who is this Report for?
1.7. Research and Analysis Methods
1.8. Frequently Asked Questions (FAQ)
1.9. Some Associated Reports
1.10. About Visiongain
 
2. What is Rheumatoid Arthritis?
2.1. What Causes Rheumatoid Arthritis?
2.2. How Does the Disease Develop?
2.3. How Can It Be Monitored?
2.4. Can RA Be Cured?
2.5. Performance Criteria Used in Clinical Trials
2.5.1. ACR Criteria For Drug Efficacy
2.5.2. HAQ-DI Measures Daily Activities
2.5.3. mSS Assesses Disease on X-Ray
2.5.4. DAS28 For Disease Severity
2.6. How is RA Treated?
2.6.1. Biologic DMARDs Are the Dominant Source of Revenue
2.6.2. Synthetic DMARDs are the Mainstay of Treatment
2.6.3. Others
2.6.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.6.3.2. Corticosteroids for Rapid Anti-Inflammatory Effect
2.6.3.3. Analgesics for Rapid Pain Relief
 
3. World Drug Market for Rheumatoid Arthritis 2016-2026
3.1. The Global Rheumatoid Arthritis Market, 2015
3.2. The Global RA Drugs Market: Revenue Forecast 2015-2026
3.3. The Global RA Drugs Market Segments: Revenue Forecast 2015-2026
3.4. Non-Biologics for RA
3.4.1. NSAIDs: Revenue Forecast, 2015-2026
3.4.2. Synthetic DMARDs: Revenue Forecast, 2015-2026
3.4.3. Others: Revenue Forecast, 2015-2026
3.5. Biologics for RA: Revenue Forecast 2015-2026
 
4. Leading Drugs in the RA Market 2016-2026
4.1. The Main Drugs in the RA Market, 2015
4.2. Humira: A Major Source of Revenue for AbbVie
4.2.1. Adalimumab Biosimilars
4.2.2. Humira: Revenue Forecast 2015-2026
4.3. Enbrel: Amgen's Revenue Protected Until 2028
4.3.1. Etanercept Biosimilars
4.3.2. Enbrel: Revenue Forecast 2015-2026
4.4. Remicade: Facing Significant Competition from Biosimilars
4.4.1. Infliximab Biosimilars
4.4.2. Remicade: Revenue Forecast 2015-2026
4.5. Rituxan: Facing Declining Market Share
4.5.1. Rituximab Biosimilars
4.5.2. Rituxan: Revenue Forecast 2015-2026
4.6. Simponi: Market Share Remaining Stable
4.6.1. Simponi: Revenue Forecast 2015-2026
4.7. Orencia: Additional Indications Being Explored
4.7.1. Abatacept Biosimilars
4.7.2. Orencia: Revenue Forecast 2015-2026
4.8. Actemra: First IL-6R Inhibitor Approved for RA
4.8.1. Tocilizumab Biosimilars
4.8.2. Actemra: Revenue Forecast 2015-2026
4.9. Cimzia: Reliable Source of Income for UCB
4.9.1. Certolizumab Biosimilars
4.9.2. Cimzia: Revenue Forecast 2015-2026
4.10. Celebrex: Facing Generic Competition
4.10.1. Celebrex: Revenue Forecast 2015-2026
4.11. Xeljanz: Good Opportunity for Revenue Growth
4.11.1. Xeljanz: Revenue Forecast 2015-2026
4.12. Arcoxia: Sales Revenue Already Declining
4.12.1. Arcoxia: Revenue Forecast 2015-2026
 
5. Leading National Markets for Rheumatoid Arthritis 2016-2026
5.1. The Leading National Markets in 2015
5.2. The Leading National Markets: Comparison of Revenues and Market Shares to 2026
5.3. The Leading National Markets: Grouped Revenue Forecasts 2016-2026
5.4. The US: Prosperous Economy and Large Patient Population Enables it to Dominate the RA Drugs Market
5.4.1. The US RA Drug Market: Revenue Forecast 2016-2026
5.5. Japan: Remains the Second Largest National Market
5.5.1. The RA Drug Market in Japan: Revenue Forecast 2016-2026
5.6. The EU5 Have 18% Market Share
5.6.1. The RA Drug Market in Germany: Revenue Forecast 2016-2026
5.6.2. The RA Drug Market in France: Revenue Forecast 2016-2026
5.6.3. The RA Drug Market in Italy: Revenue Forecast 2016-2026
5.6.4. The RA Drug Market in Spain: Revenue Forecast 2016-2026
5.6.5. The RA Drug Market in the UK: Revenue Forecast 2016-2026
5.7. China: Expanding Economy with Increasing Market Share
5.7.1. The RA Drug Market in China: Revenue Forecast 2016-2026
5.8. India: Expanding Population Driving Growth
5.8.1. The RA Drug Market in India: Revenue Forecast 2016-2026
5.9. Russia: Expansion Held Back by Troubled Economy
5.9.1. The RA Drug Market in Russia: Revenue Forecast 2016-2026
5.10. Brazil: Focus on Domestic Drug Manufacturing
5.10.1. The RA Drug Market in Brazil: Revenue Forecast 2016-2026
 
6. Rheumatoid Arthritis R&D Pipeline 2016
6.1. IL-6. Inhibitors Could Rival TNF-Inhibitors
6.1.1. Sarilumab: Already Filed With FDA
6.1.2. Sirukumab: Expected to File in Q3, 2016
6.1.3. Olokizumab: Promising Phase 2 Data
6.1.4. Clazakizumab: Alder Now Collaborating with Vitaeris
6.2. JAK Inhibitors: A Promising Class of Agents
6.2.1. Baricitinib: Potential Competitor to Xeljanz
6.2.2. Peficitinib: Selective JAK-3 Inhibitor From Astellas
6.2.3. ABT-494: Selective JAK-1 Inhibitor From AbbVie
6.2.4. Filgotinib: Following AbbVie's Withdrawal, Galapagos Now Working with Gilead
6.3. BTK Inhibitors
6.3.1. BMS-986142: Well Tolerated in Phase 1
6.3.2. HM71224: Collaboration with Eli Lilly
6.4. GM-CSF Inhibitor
6.4.1. GSK 3196165: Potential Role in Early Disease
 
7. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2016
7.1. Introduction to the Leading Companies
7.2. AbbVie: Secured Multiple Patents for Humira
7.3. Roche: Second-Leading Company
7.4. Johnson & Johnson: High Hopes for Sirukumab
7.5. Amgen: Enbrel Sales Protected in the US
7.6. Pfizer: Actively Developing Biosimilars
7.7. Merck & Co.: Remicade Sales in Decline
7.8. BMS: Exploring Additional Indications for Orencia
7.9. UCB: Reliant on Cimzia Revenue
 
8. Qualitative Analysis of the Rheumatoid Arthritis Drugs Market 2016-2026
8.1. Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2016
8.1.1. Number of Elderly Patients Expected to Rise
8.1.2. Biologics Already Recognised as a Valuable Part of Treatment
8.1.3. Biologics Used in RA Often Have Multiple Indications
8.1.4. Some Patients Have an Inadequate Treatment Response
8.1.5. Efficacy of Drugs Can Diminish Over Time
8.2. Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2016-2026
8.2.1. Need for Effective Drugs With Better Safety Profiles
8.2.2. Need for Less Invasive Routes of Administration
8.2.3. High Number of Products Will Saturate Market
8.2.4. Competition from Biosimilars Will Increase
8.3. Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2016-2026
8.3.1. Social Factors Influencing the Rheumatoid Arthritis Market
8.3.2. Technological Factors Influencing the Rheumatoid Arthritis Market
8.3.3. Economic Factors Influencing the Rheumatoid Arthritis Market
8.3.4. Political Factors Influencing the Rheumatoid Arthritis Market
8.3.4.1. Government Pressure to Control Costs
8.3.4.2. Inter-country Variability in Biosimilar Approval Process
 
9. Conclusions
9.1. Global Market for RA Drugs Will Contract After 2018
9.2. Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%
9.3. Enbrel Will Overtake Humira as the Leading Drug
9.4. US Will Remain the Dominant Market
9.5. Trends in the RA Drugs Market
 
List of Tables
Table 2.1: Biologic Agents and Mechanism of Action
Table 3.1: The RA Drugs Market by Submarket, 2015
Table 3.2: The Drugs Market for RA: Revenue ($m) Forecast, 2015-2026
Table 3.3: The RA Drugs Market Segments: Revenue ($m) Forecast, 2015-2026
Table 3.4: Non-Biologics for RA: Revenue ($m) Forecasts by Segment, 2015-2026
Table 3.5: NSAIDs: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 3.6: sDMARDs: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 3.7: Others: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 3.8: Biologics for RA: Revenue ($m) and Market Share (%) Forecasts, 2015-2026
Table 4.1: The Main Drugs in the RA Market: Revenue ($m) and Market Share (%), 2015
Table 4.2: The Main Drugs in the RA Market: Revenue ($m) Forecasts, 2015-2021
Table 4.3: The Main Drugs in the RA Market: Revenue ($m) Forecasts, 2022-2026
Table 4.4: Humira: Key Facts
Table 4.5: Adalimumab Biosimilars: Current Status, 2016
Table 4.6: Humira: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.7: Enbrel: Key Facts
Table 4.8: Etanercept Biosimilars : Current Status, 2016
Table 4.9: Enbrel: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.10: Remicade: Key Facts
Table 4.11: Infliximab Biosimilars: Current Status, 2016
Table 4.12: Remicade: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.13: Rituxan: Key Facts
Table 4.14: Rituximab Biosimilars: Current Status, 2016
Table 4.15: Rituxan: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.16: Simponi: Key Facts
Table 4.17: Simponi: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.18: Orencia: Key Facts
Table 4.19: Orencia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.20: Actemra: Key Facts
Table 4.21: Actemra: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.22: Cimzia: Key Facts
Table 4.23: Cimzia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.24: Celebrex: Key Facts
Table 4.25: Celebrex: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.26: Xeljanz: Key Facts
Table 4.27: Xeljanz: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 4.28: Arcoxia: Key Facts
Table 4.29: Arcoxia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.1: The Leading National Markets for RA: Revenue ($m) and Market Share (%), 2015
Table 5.2: RA Drugs: Market Share (%) by Country, 2015 and 2026
Table 5.3: RA Drugs: Revenue ($m) Forecast by Country, 2015-2026
Table 5.4: The US RA Drug Market: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.5: The RA Drug Market in Japan: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.6: The EU5 RA Drug Markets: Revenue ($m) Forecast, 2015-2026
Table 5.7: The RA Drug Market in Germany: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.8: The RA Drug Market in France: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.9: The RA Drug Market in Italy: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.10: The RA Drug Market in Spain: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.11: The RA Drug Market in the UK: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.12: The RA Drug Market in China: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.13: The RA Drug Market in India: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.14: The RA Drug Market in Russia: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 5.15: The RA Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecast, 2015-2026
Table 6.1: Pipeline R&D Products, 2016
Table 7.1: Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2015
Table 7.2: AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.3: Roche: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.4: J&J: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.5: Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.6: Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.7: Merck & Co.: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.8: BMS: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 7.9: UCB: Breakdown of Revenue ($m,%) by RA Drug, 2015
Table 8.1: Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2016
Table 8.2: Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2016-2026
Table 8.3: Social, Technological, Economic and Political Factors Influencing the RA Market, 2016-2026
Table 9.1: Drivers and Restraints of the RA Drugs Market, 2016-2026
 
List of Figures
Figure 1.1: Main Segments and Sub-Segments of the Rheumatoid Arthritis Market, 2016
Figure 3.1: The RA Drugs Market: Market Share (%) by Submarket, 2015
Figure 3.2: The Drugs Market for RA: Revenue ($m) Forecast, 2015-2026
Figure 3.3: The RA Drugs Market Segments: Revenue ($m) Forecast, 2015-2026
Figure 3.4: The RA Drugs Market: Market Share (%) by Segment, 2021
Figure 3.5: The RA Drugs Market: Market Share (%) by Segment, 2026
Figure 3.6: Non-Biologics for RA: Revenue ($m) Forecasts by Segment, 2015-2026
Figure 3.7: Non-Biologics for RA: Market Share (%), 2015
Figure 3.8: Non-Biologics for RA: Market Share (%), 2021
Figure 3.9: Non-Biologics for RA: Market Share (%), 2026
Figure 3.10: NSAIDs: Revenue ($m) Forecast, 2015-2026
Figure 3.11: sDMARDs: Revenue ($m) Forecast, 2015-2026
Figure 3.12: Others: Revenue ($m) Forecast, 2015-2026
Figure 3.13: Biologics for RA: Revenue ($m) Forecast, 2015-2026
Figure 4.1: The Main Drugs in the RA Market: Market Shares (%), 2015
Figure 4.2: Humira: Revenue ($m) Forecast, 2015-2026
Figure 4.3: Enbrel: Revenue ($m) Forecast, 2015-2026
Figure 4.4: Remicade: Revenue ($m) Forecast, 2015-2026
Figure 4.5: Rituxan: Revenue ($m) Forecast, 2015-2026
Figure 4.6: Simponi: Revenue ($m) Forecast, 2015-2026
Figure 4.7: Orencia: Revenue ($m) Forecast, 2015-2026
Figure 4.8: Actemra: Revenue ($m) Forecast, 2015-2026
Figure 4.9: Cimzia: Revenue ($m) Forecast, 2015-2026
Figure 4.10: Celebrex: Revenue ($m) Forecast, 2015-2026
Figure 4.11: Xeljanz: Revenue ($m) Forecast, 2015-2026
Figure 4.12: Arcoxia: Revenue ($m) Forecast, 2015-2026
Figure 5.1: RA: Market Share (%) by Country, 2015
Figure 5.2: RA: Market Share (%) by Country, 2026
Figure 5.3: The US RA Drug Market: World Market Share (%), 2015
Figure 5.4: The US RA Drug Market: Revenue ($m) Forecast, 2015-2026
Figure 5.5: The RA Drug Market in Japan: World Market Share (%), 2015
Figure 5.6: The RA Drug Market in Japan: Revenue ($m) Forecast, 2015-2026
Figure 5.7: The EU5 RA Drug Markets: World Market Share (%), 2015
Figure 5.8: The EU5 RA Drug Markets: Revenue ($m) Forecast 2015-2026
Figure 5.9: The RA Drug Market in Germany: World Market Share (%), 2015
Figure 5.10: The RA Drug Market in Germany: Revenue ($m) Forecast 2015-2026
Figure 5.11: The RA Drug Market in France: World Market Share (%), 2015
Figure 5.12: The RA Drug Market in France: Revenue ($m) Forecast, 2015-2026
Figure 5.13: The RA Drug Market in Italy: World Market Share (%), 2015
Figure 5.14: The RA Drug Market in Italy: Revenue ($m) Forecast, 2015-2026
Figure 5.15: The RA Drug Market in Spain: World Market Share (%), 2015
Figure 5.16: The RA Drug Market in Spain: Revenue ($m) Forecast, 2015-2026
Figure 5.17: The RA Drug Market in the UK: World Market Share (%), 2015
Figure 5.18: The RA Drug Market in the UK: Revenue ($m) Forecast, 2015-2026
Figure 5.19: The RA Drug Market in China: World Market Share (%), 2015
Figure 5.20: The RA Drug Market in China: Revenue ($m) Forecast, 2015-2026
Figure 5.21: The RA Drug Market in India: World Market Share (%), 2015
Figure 5.22: The RA Drug Market in India: Revenue ($m) Forecast, 2015-2026
Figure 5.23: The RA Drug Market in Russia: World Market Share (%), 2015
Figure 5.24: The RA Drug Market in Russia: Revenue ($m) Forecast, 2015-2026
Figure 5.25: The RA Drug Market in Brazil: World Market Share (%), 2015
Figure 5.26: The RA Drug Market in Brazil: Revenue ($m) Forecast, 2015-2026
Figure 7.1: Leading Companies in the RA Drug Market: Market Share (%), 2015
Figure 7.2: AbbVie: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.3: Roche: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.4: J&J: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.5: Amgen: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.6: Pfizer: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.7: Merck & Co: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.8: BMS: Breakdown of Revenue (%) by RA Drug, 2015
Figure 7.9: UCB: Breakdown of Revenue (%) by RA Drug, 2015
Figure 9.1: RA Drugs Market: Comparison of Revenue ($m) Forecasts for Total Market and Market for RA Indication, 2015-2026
Figure 9.2: RA Drugs Market: Comparison of Revenue ($m) Forecasts for Biologic and Non-Biologic Segments, 2015-2026
Figure 9.3: The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2015, 2021, 2026
Figure 9.4: The Leading National Markets for RA Drugs: Revenue ($m) Forecasts, 2015, 2021, 2026
 
Companies Listed
Abbott Laboratories
AbbVie Inc
Ablynx NV
Agência Nacional de Vigilância Sanitária (ANVISA) Brazil
Alder Biopharmaceuticals
American College of Rheumatology
Amgen Inc
Astellas Pharma
Baxalta
Biocad
Biocon
Biogen
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Can-Fite BioPharma
Celltrion Inc
Chugai Pharmaceutical Co
Cipla
Coherus BioSciences
Committee for Medicinal Products for Human Use (CHMP)
Covagen
Daiichi Sankyo
Dr. Reddy's Laboratories
Drug Effectiveness Review Project, US
Eli Lilly
European Medicines Agency (EMA)
Epirus Biopharmaceuticals
European Commission
F Hoffman-La Roche AG (Roche)
Food and Drug Administration (FDA)
Fujifilm Corporation
Galapagos NV
Genentech
Gilead Sciences
GlaxoSmithKline (GSK)
Hanmi Pharmaceutical Co
Hanwha Biologics
Hanwha Chemical Corp
Hetero Healthcare
Incyte Corporation
Institut fur Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Germany
Institute for Clinical and Economic Review, US
Intas Pharmaceuticals
Janssen Biologics
Janssen Biotech
Janssen Pharmaceutical Companies
Johnson & Johnson (J&J)
Kyowa Hakko Kirin Co
LG Life Sciences
Merck & Co.
Merck KGaA
Merck, Sharp & Dohme Corp (MSD)
Ministry of Food and Drug Safety, South Korea
Ministry of Health, Italy
Ministry of Health, Labor and Welfare (MHLW), Japan
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals
MorphoSys
Mycenax Biotech
Mylan
National Health Service (NHS), UK
National Institute for Health and Care Excellence (NICE), UK
National Institute for Health Research (NIHR), UK
Nichi-Iko Pharmaceutical Co
Novartis International
Oncobiologics
Pfizer
Protalix Biotherapeutics
Regeneron Pharmaceuticals
Samsung Bioepis Co
Samsung BioLogics
Sandoz
Sanofi
Servizio Sanitario Nazionale (SSN), Italy
Shanghai Celgen Bio-Pharmaceutical Co
Shanghai CP Guojian Pharmaceutical Co
Simcere Pharmaceutical Group
Sistema Único de Saúde (SUS) Brazil
Sun Pharmaceutical Industries
Takeda Pharmaceutical Co
TSH Biopharm Corporation
UCB
US Patent Office
Vitaeris
World Bank
World Health Organization (WHO)
Zydus Cadila

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统